Human(613) Summary: A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Save up to 60% per TRCN when you buy a set with the same options.
MISSION® siRNAs have been designed using a world-class siRNA design algorithm licensed from Rosetta Inpharmatics, a leader in advanced siRNA research. The Rosetta-powered siRNA design algorithm has been optimized with over 3 years of continuous development for enhanced performance in RNAi applications. New and critical siRNA design rules incorporated into the latest algorithm lead to increased target specificity and knockdown for low abundance messages.
Validated MISSION® siRNAs have been functionally validated in Hela cells by Sigma scientists to Knockdown gene expression by 75% or greater. With Validated MISSION® siRNAs, we have done the upfront validation work, so that you do not have to.